Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD 1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. - Bailey,R.; Kris,M.; Wolf,M. (Proc Am Assoc Cancer Res, 2003)